COVID 19 drug Paxlovid
As the number of Omicron cases continues to increase in India and worldwide, recently approved antiviral pills could be a game-changer for the most vulnerable. However, the experts have cautioned that some of these new medications may not be safe for everyone and might require careful monitoring by doctors and pharmacists.
The FDA had recently given approval for Emergency Use Authorisation (EUA) Paxlovid, developed by Pfizer Inc for treating mild-to-moderate Covid-19 in adults and children 12 years and older, who are likely to be at greater risk for severe infection. This came after the fact that in clinical trials Paxlovid was shown to reduce COVID-19-related hospitalization or death from any cause by 89% compared to placebo in patients treated within three days of symptom onset.
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)